Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 13, 2019
- Accepted in final form January 31, 2020
- First Published March 17, 2020.
Author Disclosures
- Darius Häusler, PhD*,
- Zivar Hajiyeva, MD*,
- Jan W. Traub, MD,
- Scott S. Zamvil, MD, PhD,
- Patrice H. Lalive, MD,
- Wolfgang Brück, MD and
- Martin S. Weber, MD
- Darius Häusler, PhD*,
- Zivar Hajiyeva, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jan W. Traub, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Scott S. Zamvil, MD, PhD,
Dr. Zamvil has received honoraria for serving on Data Safety Monitoring Boards for MS trials conducted by Opexa, BioMS, Teva Pharmaceuticals, Inc. and Eli Lilly and Co. He is a member of the Clinical Advisory Board for the Myelin Repair Foundation.
NONE
(1) Biogen - Speaker honoraria and advisory board meetings (2) Teva - Speaker honoraria and advisory board meetings
(1) Neurology, Neuroimmunology and Neuroinflammation, Deputy Editor, 2014-present
"Aquaporin-4 peptides and methods for using same" (SF2010-074; USF-461PRV (pending). The application describes the discovery of aquaporin-4 T cell determinants in neuromyelitis optica patients and the use for antigen-specific tolerance.
NONE
NONE
SSZ has served as a consultant to Biogen Idec, Teva Neuroscience, EMD-Serono, Genzyme, Novartis and Roche.
Advanced Health Media, 2009-present Biogen, 2009-present
NONE
NONE
(1) Biogen - speaker and advisory board meetings (2) Teva - speaker and advisory board meetings (3) Genentech - advisory board meeting (4) Novartis - advisory board meetings (5) Genzyme - advisory board meetings (6) Alexion - advisory board meeting
NIH RO1 NS092835-01 NIH RO1 AI131624-O1A1 NIH R21 NS10815990-01
NMSS RG 1701-26628 NMSS RG 1801-29861
Alexander M. and June L. Maisin Foundation, PI
NONE
NONE
NONE
NONE
NONE
NONE
- Patrice H. Lalive, MD,
(1) Biogen-Idec (2) Novartis (3) Merck (4) Roche
NONE
(1) Biogen-Idec (2)Teva (3) Merck (4) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wolfgang Brück, MD and
- Martin S. Weber, MD
Evobrutinib Phase II steering committee
NONE
He received travel funding and/or speaker honoraria from Biogen-Idec, Merck Serono, Novartis, Roche, TEVA, Bayer and Genzyme.
Academic Editor for PLoS One
NONE
NONE
NONE
NONE
NONE
NONE
NONE
He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.
He receives research support from the National Multiple Sclerosis Society (NMSS; PP 1660), the Deutsche Forschungsgemeinschaft (DFG; WE 3547/4-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute of Neuropathology (D.H., J.W.T., W.B., M.S.W.), University Medical Center; Department of Neurology (Z.H., J.W.T., M.S.W.), University Medical Center, Göttingen, Germany; Department of Neurology (S.S.Z.), University of California, San Francisco; Division of Neurology (P.H.L.), Department of Neurosciences, Hospital and University of Geneva; and Department of Pathology and Immunology (P.H.L.), Faculty of Medicine, Geneva, Switzerland.
- Correspondence
Dr. Weber martin.weber{at}med.uni-goettingen.de
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Glatiramer acetate treatment negatively regulates type I interferon signalingNicolas Molnarfi, Thomas Prod'homme, Ulf Schulze-Topphoff et al.Neurology - Neuroimmunology Neuroinflammation, November 09, 2015 -
Article
EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MSGisella Guerrera, Serena Ruggieri, Mario Picozza et al.Neurology: Neuroimmunology & Neuroinflammation, August 17, 2020 -
Articles
Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosisSuhayl Dhib-Jalbut et al.Neurology, June 04, 2007 -
Articles
Multiple sclerosis immunologyThe healthy immune system vs the MS immune systemLloyd H. Kasper, Jennifer Shoemaker et al.Neurology, December 28, 2009